ProCE Banner Activity

Experts Address Questions on the Use of Immunotherapy for Resectable and Unresectable Melanoma in Today’s Practice

Clinical Thought

A panel of expert faculty answer audience questions from a live webinar on the latest data on immunotherapy in resectable and unresectable melanoma.

Released: July 19, 2023

Share

Faculty

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Evan J. Lipson

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Michael Postow

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This program is intended for oncologists and other multidisciplinary care team members involved in the care of patients with melanoma.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations for immunotherapy (collectively PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) and targeted therapies (BRAF/MEK inhibitors) in early-stage and advanced-stage melanoma.

Disclosure

Program Director

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD: consultant/advisor/speaker: Bristol Myers Squibb, Immatics, Instil Bio, Iovance, Lyell Immunopharma, Novartis, Pfizer; researcher: Iovance

Primary Author

Evan J. Lipson, MD

Associate Professor of Oncology
Melanoma and Cancer Immunology Programs
Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins University School of Medicine
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Evan J. Lipson, MD: consultant/advisor/speaker: Bristol Myers Squibb, CareDx, Eisai, Genentech, Immunocore, Instil Bio; researcher: Bristol Myers Squibb, Merck, Sanofi/Regeneron.

Michael Postow, MD

Chief, Melanoma Service
Associate Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Michael Postow, MD: consultant/advisor/speaker: Bristol Myers Squibb, Chugai, Eisai, Merck, Nektar, Novartis, Pfizer, Replimune; researcher: Bristol Myers Squibb, Infinity, Merck, Novartis, RGenix.